Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q4 2022 call → NOThe question asks whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket — with three conditions: (1) paying now for something not yet earning, (2) the wait is the main current work, (3) the far side is a specific, near-dated, already-visible event within roughly a year, depending on work already in motion. Let me scan the transcript for such a situation. Key candidates: - The pulmonary programs (ARO-RAGE, ARO-MUC5AC) — in Phase 1/2, expecting interim data in first half of 2023. But these are clinical trials, not a "waiting period" with costs being borne for something not yet earning in the sense described. - The 20 in '25 program — future pipeline expansion. - The olpasiran royalty sale — that's a financing, not a waiting period. - The AAT program — SEQUOIA data and Phase 3 design, expecting feedback soon. But again, this is clinical development, not a defined waiting period with costs being borne for a facility or asset. The question is quite specific: it's about a company bearing real, ongoing cash or earnings cost for something whose benefit has not arrived yet, with the end being a specific near-dated event. Examples given: people hired and being paid whose work hasn't begun producing; a facility being carried before it operates; inventory bought for volume not yet shipping; a program being funded before it yields anything. Looking at the transcript, management mentions: - "we expect capital expenditures up to $200 million as we near completion on our footprint expansion projects, including GMP manufacturing." — This is a facility expansion being built. But is it described as a waiting period being paid for now? They mention capital expenditures, but they don't frame it as "we are currently paying for this facility that isn't yet earning, and the end is near." They just mention it as a financial item. - The pulmonary programs: they are in Phase 1/2, expecting interim data in first half of 2023. This is a clinical trial — the company is paying for the trial, and the benefit (proof of concept) hasn't arrived. But is this framed as a "waiting period" the company is standing in? Management says "We anticipate that we will be able to report interim results from Part 1 of these studies and begin Part 2 in patients with asthma in the first half of 2023." This is a near-dated event.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.